Second Focus Diagnostics' flu test cleared via emergency use authorisation
This article was originally published in Clinica
The US FDA has granted emergency use authorisation (EUA) for Focus Diagnostics' Simplexa Influenza A H1N1 (2009) test. It runs on the 3M Integrated Cycler, a PCR-based system that is not yet FDA-approved, which provides results in 30-75 minutes. The test can now be used by the estimated 6,500 CLIA high-complexity labs in the US, including certain hospitals and regional labs. It could therefore help health services cope with a surge in testing demands, Focus – a wholly-owned subsidiary of Quest Diagnostics – believes. In July, the FDA granted an EUA for Focus' 2009 H1N1 flu test, making it the first diagnostic to receive such an approval (www.clinica.co.uk, July 27 2009).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.